Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy

Bio-Techne (NASDAQ: TECH) has announced a strategic distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system.

The collaboration aims to support the development of monoclonal antibody and gene therapy products worldwide. With over 160 approved antibody therapies globally, the partnership addresses critical quality control needs in both mAb development and the rapidly growing gene therapy sector. The integration of USP reference standards with Bio-Techne's analytical instruments will enable therapy manufacturers to achieve reliable characterization for purity, charge, size, and identity applications throughout product development.

https://www.stocktitan.net/news/TECH/bio-techne-and-usp-announce-collaboration-to-accelerate-monoclonal-ew1ldgmzalo4.html